Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Significant Growth in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 145,500 shares, a growth of 63.3% from the October 31st total of 89,100 shares. Approximately 2.7% of the shares of the company are sold short. Based on an average trading volume of 340,600 shares, the short-interest ratio is currently 0.4 days.

Protagenic Therapeutics Stock Down 1.3 %

Shares of NASDAQ PTIX traded down $0.01 during midday trading on Friday, hitting $0.59. The company had a trading volume of 115,991 shares, compared to its average volume of 364,659. Protagenic Therapeutics has a twelve month low of $0.49 and a twelve month high of $1.87. The business has a 50-day simple moving average of $0.62 and a two-hundred day simple moving average of $0.79. The firm has a market capitalization of $4.01 million, a price-to-earnings ratio of -0.46 and a beta of 0.24.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.